Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.203,20
-0,84%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Lantern Pharma Inc (LTRN) Lantern Pharma Inc (LTRN) Notizie

Lantern Pharma Inc

LTRN
5,23
-0,23 (-4,21%)
26 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202414:00BWLantern Pharma Launches “Webinar Wednesdays” Featuring..
22/4/202414:12BWLantern Pharma Receives Regulatory Approval to Expand..
18/3/202421:02BWLantern Pharma Reports Fourth Quarter & Fiscal Year 2023..
18/3/202412:12IHMARKETNEWSAnticipation Builds on Wall Street for Federal Reserve’s..
15/3/202413:00BWLantern Pharma Announces Initial Patients Dosed in..
11/3/202412:30BWLantern Pharma to Report Fourth Quarter and Fiscal Year 2023..
05/3/202414:01BWLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st..
04/3/202414:01BWLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion..
01/3/202403:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202414:01BWLantern Pharma Advances Unique ADC (Antibody Drug Conjugate)..
19/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202413:30BWStarlight Therapeutics, a Subsidiary of Lantern Pharma..
29/12/202322:05EDGAR2Form 8-K - Current report
01/12/202312:02EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202312:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202314:00BWFDA Grants Lantern Pharma Orphan Drug Designation for Drug..
24/11/202322:05EDGAR2Form 8-K - Current report
08/11/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:05EDGAR2Form 8-K - Current report
08/11/202322:01BWLantern Pharma Reports Third Quarter 2023 Financial Results..
01/11/202313:00BWLantern Pharma to Report Third Quarter 2023 Operating &..
20/10/202323:25EDGAR2Form 8-K - Current report
10/10/202314:00BWLantern Pharma to Present at the ThinkEquity Conference on..
03/10/202314:00BWLantern Pharma Announces Publication in Clinical Cancer..
25/9/202314:30BWLantern Pharma Announces First Patient Dosed in the Phase 1..
18/9/202315:00BWLantern Pharma Receives IND Clearance from FDA Enabling..
31/8/202314:00BWLantern Pharma to Present Data Highlighting the Anti-Tumor..
28/8/202314:00BWLantern Pharma Expands AI Capabilities of RADR® Platform to..
14/8/202314:30BWLantern Pharma Receives Notice of US Patent Allowance for..
09/8/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:05EDGAR2Form 8-K - Current report
09/8/202322:01BWLantern Pharma Reports Second Quarter 2023 Financial Results..
02/8/202314:00BWLantern Pharma to Report Second Quarter 2023 Operating &..
17/7/202314:00BWLantern Pharma to Participate and Present at Multiple..
26/6/202314:30BWOncotarget Publishes New Data by Lantern Pharma, an AI..
12/6/202314:30BWLantern Pharma Receives FDA Clearance of IND Application for..
08/6/202315:00BWLantern Pharma Leverages AI Platform, RADR®, to Develop..
17/5/202314:00BWLantern Pharma to Present at the Lytham Partners Spring 2023..
09/5/202322:01BWLantern Pharma Reports First Quarter 2023 Financial Results..
03/5/202315:00PRNUSLantern Pharma Selects REPROCELL USA to Provide Support for..
02/5/202322:01BWLantern Pharma to Report First Quarter 2023 Operating &..
02/5/202313:30BWLantern Pharma Develops Top-Ranked AI Algorithms to Predict..
Apertura: 5,55 Min: 5,42 Max: 6,04
Chiusura: 5,46

La tua Cronologia

NASDAQ
LTRN
Lantern Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network